Haleon plc(HLN) - 2024 Q3 - Quarterly Report

Haleon plc: Proposed Off-Market Purchase Alongside Pfizer Inc. Offering Haleon plc plans an off-market share purchase from Pfizer Inc., allocating shares for its 2024 buyback program and 2025 employee share plans, contingent on Pfizer's offering Transaction Overview Haleon plc agreed to an off-market purchase of its shares from Pfizer Inc. for approximately £230 million, contingent on Pfizer's accelerated bookbuild offering - Pfizer Inc. announced a proposed offering of Haleon plc ordinary shares to institutional investors through an accelerated bookbuild process[5] Haleon's Off-Market Purchase Details | Parameter | Details | | :--- | :--- | | Total Purchase Value | Approximately £230 million | | Seller | Pfizer Inc. | | Condition | Subject to completion of Pfizer's Proposed Offering | | Purchase Price | Equal to the offering price per share in Pfizer's Proposed Offering | Allocation and Purpose of Purchased Shares The £230 million worth of shares purchased from Pfizer are allocated for completing the 2024 share buyback program and satisfying 2025 employee share plan obligations Breakdown of Share Purchase Allocation | Purpose | Amount | Share Treatment | | :--- | :--- | :--- | | 2024 Share Buyback Program | ~£114.6 million | To be cancelled | | 2025 Employee Share Plans | ~£115.4 million | To be held as treasury shares | Impact on Share Buyback Programme This off-market transaction fulfills the remaining 2024 share buyback allocation, leading to the termination of Haleon's on-market share buyback program - The purchase represents the remainder of the £500 million allocated to share buybacks in 2024[7] - Haleon intends to cancel these ordinary shares and end its on-market share buyback programme that was launched on August 1, 2024[7] About Haleon Haleon is a global consumer health leader with a diversified product portfolio across five major categories and established brands Company Profile Haleon is a global leader in consumer health, offering a diversified product portfolio across five major categories with well-established brands - Haleon's product portfolio spans five major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS)[11] - Its portfolio includes long-standing brands such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum[11]